You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Tailoring Targeted Therapy: New Directions for Managing Patients Across the Spectrum of Non-Small Cell Lung Cancer

  • Authors: Zofia Piotrowska, MD; Joshua Sabari, MD; Anjali Saqi, MD, MBA; Boris Sepesi, MD, FACS
  • CME / ABIM MOC Released: 7/26/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 7/26/2023, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for oncologists and other healthcare team members participating in the care of patients with NSCLC.

The goal of this activity is that learners will be better able to understand treatment strategies for patients with NSCLC and specific molecular alterations and improve their ability to personalize care for these patients as part of the multidisciplinary team.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data analyzing therapies for patients with metastatic NSCLC and specific molecular alterations
    • Key clinical data evaluating treatment strategies for patients with early-stage NSCLC and specific molecular alterations
  • Have greater competence related to
    • Identifying specific molecular alterations in patients with NSCLC
    • Creating a customized care plan for patients with NSCLC and specific molecular alterations
  • Demonstrate greater confidence in their ability to
    • Coordinate with the multidisciplinary team to optimize care for patients with NSCLC and specific molecular alterations


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Chair/Moderator

  • Zofia Piotrowska, MD

    Assistant Professor of Medicine
    Harvard Medical School
    Attending Physician
    Massachusetts General Hospital
    Boston, Massachusetts

    Disclosures

    Zofia Piotrowska, MD, has the following relevant financial relationships:
    Consultant or advisor for: Blueprint; C4 Therapeutics; Cullinan; Daiichi Sankyo; Eli Lilly; Janssen; Jazz Pharmaceuticals; Takeda
    Research funding from: AbbVie; AstraZeneca; Blueprint; Cullinan; Daiichi Sankyo; Janssen; Novartis; Spectrum; Takeda; Tesaro/GlaxoSmithKline

Faculty

  • Joshua Sabari, MD

    Assistant Professor of Medicine
    NYU Grossman School of Medicine
    Thoracic Medical Oncologist
    NYU Langone Health Perlmutter Cancer Center
    New York, New York

    Disclosures

    Joshua Sabari, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Genentech; Janssen; Mirati; Novartis; Pfizer; Sanofi Genzyme; Takeda

  • Anjali Saqi, MD, MBA

    Professor of Pathology and Cell Biology
    Director, Pulmonary Pathology
    Columbia University Medical Center
    New York, New York

    Disclosures

    Anjali Saqi, MD, MBA, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb; Genentech; Roche; Veracyte
    Research funding from: Boehringer Ingelheim; Genentech
    Patent beneficiary of: Genentech
    Other: Honorarium: Dedham; Kantar Health; Fieldworks/Inspirata; Qessential Medical Market Research

  • Boris Sepesi, MD, FACS

    Associate Professor
    Department of Thoracic and Cardiovascular Surgery
    Division of Surgery
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Boris Sepesi, MD, FACS, has no relevant financial relationships.

Editor

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC

    Disclosures

    Amy Furedy, RN, OCN, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Tailoring Targeted Therapy: New Directions for Managing Patients Across the Spectrum of Non-Small Cell Lung Cancer

Authors: Zofia Piotrowska, MD; Joshua Sabari, MD; Anjali Saqi, MD, MBA; Boris Sepesi, MD, FACSFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 7/26/2022

Valid for credit through: 7/26/2023, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to understand treatment strategies for patients with non-small cell lung cancer and specific molecular alterations and improve their ability to personalize care for these patients as part of the multidisciplinary team.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print